skip banner navigation
National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Breast Cancer and Pregnancy (PDQ®)
Patient VersionHealth Professional VersionEn EspañolLast Modified: 07/21/2004




General Information






Stage Information






Treatment Option Overview






Other Considerations for Pregnancy and Breast Cancer






Early Stage Breast Cancer (Stage I and II)






Late Stage Breast Cancer (Stage III and IV)






Changes to This Summary (07/21/2004)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Dictionary

Funding Opportunities

NCI Publications

NCI Calendar

Español
NCI Highlights
October is Breast Cancer Awareness Month

NCI Annual Progress Report on Cancer Research 2003

Women, Tobacco and Cancer: Agenda for 21st Century

Past Highlights
Need Help?
General Information

Breast cancer is the most common cancer in pregnant and postpartum women, occurring in about 1 in 3,000 pregnant women. The average patient is between 32 to 38 years of age and, with many women choosing to delay childbearing, it is likely that the incidence of breast cancer during pregnancy will increase.

Breast cancer pathology is similar in age-matched pregnant and nonpregnant women. Hormone receptor assays are usually negative in pregnant breast cancer patients, but this may be the result of receptor binding by high serum estrogen levels associated with the pregnancy. Enzyme immunocytochemical receptor assays, however, are more sensitive than competitive binding assays. A study using binding methods indicated similar receptor positivity between pregnant and nonpregnant women with breast cancer.[1] The study concluded that increased estrogen levels during pregnancy could result in a higher incidence of receptor positivity detected with immunohistochemistry than is detected by radiolabeled ligand binding, which is because of competitive inhibition by high levels of endogenous estrogen.

The natural tenderness and engorgement of the breasts of pregnant and lactating women may hinder detection of discrete masses, and therefore, early diagnoses of breast cancer. Delays in diagnoses are common, with an average reported delay of 5 to 15 months from the onset of symptoms.[2-5] Because of this delay, cancers are typically detected at a later stage than in a nonpregnant, age-matched population.[6] To detect breast cancer, pregnant and lactating women should practice self-examination and undergo a breast examination as part of the routine prenatal examination by a doctor. If an abnormality is found, diagnostic approaches such as ultrasound and mammography may be used. With proper shielding, mammography poses little risk of radiation exposure to the fetus.[7] Mammograms should only be used, however, to evaluate dominant masses and to locate occult carcinomas in the presence of other suspicious physical findings.[7] Since at least 25% of mammograms in pregnancy may be negative in the presence of cancer, a biopsy is essential for the diagnosis of any palpable mass. Diagnosis may be safely accomplished with a fine-needle aspiration or excisional biopsy under local anesthesia. To avoid a false-positive diagnosis as a result of misinterpretation of pregnancy-related changes, the pathologist should be advised that the patient is pregnant.[8,9]

Overall survival of pregnant women with breast cancer may be worse than in nonpregnant women at all stages;[10] however, this may be due primarily to delayed diagnoses.[11] Termination of pregnancy has not been shown to have any beneficial effect on breast cancer outcome and is not usually considered as a therapeutic option.[2,3,5,7,12] Termination of pregnancy, however, may be considered, based on the age of the fetus, and if maternal treatment options, such as chemotherapy and radiation therapy, are significantly limited by the continuation of the pregnancy.

References

  1. Elledge RM, Ciocca DR, Langone G, et al.: Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer 71 (8): 2499-506, 1993.  [PUBMED Abstract]

  2. Hoover HC Jr: Breast cancer during pregnancy and lactation. Surg Clin North Am 70 (5): 1151-63, 1990.  [PUBMED Abstract]

  3. Gwyn K, Theriault R: Breast cancer during pregnancy. Oncology (Huntingt) 15 (1): 39-46; discussion 46, 49-51, 2001.  [PUBMED Abstract]

  4. Moore HC, Foster RS Jr: Breast cancer and pregnancy. Semin Oncol 27 (6): 646-53, 2000.  [PUBMED Abstract]

  5. Rugo HS: Management of breast cancer diagnosed during pregnancy. Curr Treat Options Oncol 4 (2): 165-73, 2003.  [PUBMED Abstract]

  6. Clark RM, Chua T: Breast cancer and pregnancy: the ultimate challenge. Clin Oncol (R Coll Radiol) 1 (1): 11-8, 1989.  [PUBMED Abstract]

  7. Barnavon Y, Wallack MK: Management of the pregnant patient with carcinoma of the breast. Surg Gynecol Obstet 171 (4): 347-52, 1990.  [PUBMED Abstract]

  8. Novotny DB, Maygarden SJ, Shermer RW, et al.: Fine needle aspiration of benign and malignant breast masses associated with pregnancy. Acta Cytol 35 (6): 676-86, 1991 Nov-Dec.  [PUBMED Abstract]

  9. Finley JL, Silverman JF, Lannin DR: Fine-needle aspiration cytology of breast masses in pregnant and lactating women. Diagn Cytopathol 5 (3): 255-9, 1989.  [PUBMED Abstract]

  10. Guinee VF, Olsson H, Möller T, et al.: Effect of pregnancy on prognosis for young women with breast cancer. Lancet 343 (8913): 1587-9, 1994.  [PUBMED Abstract]

  11. Petrek JA, Dukoff R, Rogatko A: Prognosis of pregnancy-associated breast cancer. Cancer 67 (4): 869-72, 1991.  [PUBMED Abstract]

  12. Gallenberg MM, Loprinzi CL: Breast cancer and pregnancy. Semin Oncol 16 (5): 369-76, 1989.  [PUBMED Abstract]

Back to TopBack to Top

Next Section >

skip footer navigation

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health FirstGov.gov